PMID- 37355791
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230626
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 71
IP  - 4
DP  - 2023 Apr
TI  - Dyspepsia - The Indian perspective: A cross sectional study on demographics and 
      treatment patterns of Dyspepsia from across India (Power 1.0 study).
PG  - 11-12
LID - 10.5005/japi-11001-0231 [doi]
AB  - BACKGROUND: Dyspepsia includes a spectrum of symptoms ranging from epigastric 
      pain and early satiety to postprandial fullness. The worldwide prevalence of 
      dyspepsia is 20-30%. It is slightly higher in the Western population and occurs 
      more frequently among women. While the precise prevalence of dyspepsia in India 
      is not available, different studies estimate that it affects 7.6-49% of the 
      Indian population. Through our current study, we wanted to understand the 
      demographics, clinical profile, patient presentation, and management in India. We 
      also wanted to document the pattern of use of proton pump inhibitors (PPI) and 
      patient satisfaction with PPIs in Indian patients with dyspepsia. MATERIALS AND 
      METHODS: This pan-India, multi-centric, cross-sectional, questionnaire-based, 
      noninterventional, observational study was conducted between February and October 
      2021 in patients >18 years of age with a clinical diagnosis of any form of 
      dyspepsia. Descriptive statistics were used for categorical variables, and 
      between-group comparisons were made using Fischer's exact test, with p < 0.05 
      denoting statistical significance. RESULTS: A total of 3,739 patients from across 
      29 states of India participated in the study. Most of the patients were male 
      (70.8%) and were from urban areas (56.8%). The highest percentage of patients 
      were aged 31-40 (33.8%), and most patients (60.2%) had dyspepsia for a duration 
      of 6-12 months. Patients with functional dyspepsia (FD) (78.5%) were 
      significantly higher compared to organic dyspepsia (OD) (21.5%) (p < 0.001). 
      The most frequent presenting symptoms were epigastric pain, nausea, vomiting, and 
      heartburn. A quarter (25.6%) of the dyspepsia patients were associated with 
      various comorbid conditions, of which diabetes mellitus, hypertension, and 
      irritable bowel syndrome are the most common ones. A total of 619 patients in the 
      study were on concomitant medications, of which the most common were antidiabetic 
      drugs (271/619, 43.8%). Rabeprazole was the most frequently used PPI (2467/3739, 
      66.0%) among the study participants. The patient satisfaction analysis showed 
      that, overall, patients were satisfied with PPIs, as most patients (~80%) agreed 
      to almost all questions. The analysis for individual PPIs showed the highest 
      "agree" responses in the rabeprazole group for almost all questions (12 of 13). 
      Around 86.4% of patients on rabeprazole agreed with "immediate relief from 
      acidity," 84.9% for "gives me complete relief," and 85.9% for "relief from 
      nighttime acidity symptoms." CONCLUSION: Our study involving over 3,700 Indian 
      patients with Dyspepsia adds to the growing knowledge of dyspepsia in India. 
      Dyspepsia is more prevalent in males and in the 31-50 age group. FD is the most 
      common form. Overall, patients were satisfied with PPIs in dyspepsia management 
      in India. Patients on rabeprazole showed higher levels of medication adherence, 
      satisfaction with symptom relief, convenience of therapy, and safety compared to 
      patients on other PPIs. Against the backdrop of a paucity of reliable data about 
      dyspepsia in India, our study results provide valuable insights into Dyspepsia 
      and its management in an Indian setting.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Sud, Randhir
AU  - Sud R
AD  - Consultant, Specialist Clinic, Delhi.
FAU - Pebbili, Kranthi Kiran
AU  - Pebbili KK
AD  - Cluster Head Recura Division.
FAU - Desai, Shashank Ashit
AU  - Desai SA
AD  - Medical Advisor, Department of Medical Affairs, Dr Reddys Laboratories, 
      Telangana, Hyderabad.
FAU - Bhagat, Seema
AU  - Bhagat S
AD  - Clinical Research Specialist.
FAU - Rathod, Rahul
AU  - Rathod R
AD  - Cluster Head Ideation and Clinical Research.
FAU - Mane, Amey
AU  - Mane A
AD  - Cluster Head Acute Division.
FAU - Kotak, Bhavesh
AU  - Kotak B
AD  - Head, Department of Medical Affairs, Dr Reddys Laboratories, Telangana, 
      Hyderabad, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 32828355LL (Rabeprazole)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Adolescent
MH  - Adult
MH  - Middle Aged
MH  - *Dyspepsia/epidemiology/diagnosis
MH  - Rabeprazole/therapeutic use
MH  - Cross-Sectional Studies
MH  - Proton Pump Inhibitors/therapeutic use
MH  - India/epidemiology
MH  - Pain
MH  - Demography
EDAT- 2023/06/25 06:42
MHDA- 2023/06/26 06:41
CRDT- 2023/06/25 02:50
PHST- 2023/06/26 06:41 [medline]
PHST- 2023/06/25 06:42 [pubmed]
PHST- 2023/06/25 02:50 [entrez]
AID - 10.5005/japi-11001-0231 [doi]
PST - ppublish
SO  - J Assoc Physicians India. 2023 Apr;71(4):11-12. doi: 10.5005/japi-11001-0231.